Evidence map›Paper›PMID 28448023›Full record

ArticleJournal of visualized experiments : JoVE2017

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells.

Kathryn E Ware, Shivee Gilja, Shenghan Xu, Samantha Shetler, Mohit K Jolly, Xueyang Wang, Suzanne Bartholf Dewitt, Alexander J Hish, Sarah Jordan, William Eward and 3 more

Abstract readVideo-Audio Media
In one paragraph

Article in Journal of visualized experiments : JoVE, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Epithelioid sarcoma of the scalp: a case report and literature review.International journal of clinical and experimental pathology · 2019
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Kathryn E WareDepartment of Medicine, Duke University.
Shivee GiljaDepartment of Medicine, Duke University.
Shenghan XuDepartment of Medicine, Duke University.
Samantha ShetlerDepartment of Medicine, Duke University.
Mohit K JollyDepartment of Bioengineering, Rice University.
Xueyang WangDepartment of Molecular Genetics and Microbiology, Duke University.
Suzanne Bartholf DewittSolid Tumor Program and the Duke Prostate Center, Duke University Medical Center.
Alexander J HishDepartment of Medicine, Duke University.
Sarah JordanDepartment of Medicine, Duke University.
William EwardDuke University Medical Center.
Herbert LevineDepartment of Bioengineering, Rice University.
Andrew J ArmstrongSolid Tumor Program and the Duke Prostate Center, Duke University Medical Center.
Jason A SomarelliDepartment of Medicine, Duke University; jason.somarelli@duke.edu.

Funding

AR variant regulation during EMT and disease progressionF32CA192630 · NCI · DUKE UNIVERSITY · PI WARE, KATHRYN · 2015 to 2017
$173k
NCI NIH HHS F32 CA192630
6 · The paper itself

Abstract

Phenotypic plasticity refers to a phenomenon in which cells transiently gain traits of another lineage. During carcinoma progression, phenotypic plasticity drives invasion, dissemination and metastasis. Indeed, while most of the studies of phenotypic plasticity have been in the context of epithelial-derived carcinomas, it turns out sarcomas, which are mesenchymal in origin, also exhibit phenotypic plasticity, with a subset of sarcomas undergoing a phenomenon that resembles a mesenchymal-epithelial transition (MET). Here, we developed a method comprising the miR-200 family and grainyhead-like 2 (GRHL2) to mimic this MET-like phenomenon observed in sarcoma patient samples.We sequentially express GRHL2 and the miR-200 family using cell transduction and transfection, respectively, to better understand the molecular underpinnings of these phenotypic transitions in sarcoma cells. Sarcoma cells expressing miR-200s and GRHL2 demonstrated enhanced epithelial characteristics in cell morphology and alteration of epithelial and mesenchymal biomarkers. Future studies using these methods can be used to better understand the phenotypic consequences of MET-like processes on sarcoma cells, such as migration, invasion, metastatic propensity, and therapy resistance.

Indexed as

Cell CountCell Line, TumorDNA-Binding ProteinsEpithelial CellsEpithelial-Mesenchymal TransitionGene Expression RegulationHumansMicroRNAsSarcomaTranscription FactorsTransfectionDNA-Binding ProteinsGRHL2 protein, humanMicroRNAsMIRN200 microRNA, humanTranscription Factors

Identifiers

PMID28448023
PMCPMC5564486

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.